Ovoca Bio PLC Holding(s) in Company (5916A)

TIDMOVB

RNS Number : 5916A

Ovoca Bio PLC

23 January 2024

Ovoca Bio plc

("Ovoca" or the "Company")

Holding(s) in Company

Dublin, Ireland, January 23, 2024 - Ovoca Bio, a biopharmaceutical company with a focus on women's health, received notification from Mr. Leonid Skoptsov on 16 January 2024 that, as of 17 October 2023, he holds an interest in 10,002,078 ordinary shares of nominal value EUR0.125 each, which represents 12.26%* of the Company's issued share capital (excluding treasury shares) . The Company also received notification from Mr. Alexandr Mogutov on 16 January 2024 that, as of 17 October 2023, he no longer has a notifiable interest in the Company's issued share capital (excluding treasury shares).

*This percentage shareholding is based on a share in issue figure of 81,563,806 ordinary shares of nominal value EUR0.125 each. The Company also holds 6,895,000 ordinary shares in treasury, which do not carry voting rights.

End

For further information:

Ovoca Bio plc

Kirill Golovanov (Chief Executive)

Tel [phone]

[e-mail]

Davy (Nominated Adviser, Euronext Growth Listing Sponsor and Broker)

Ivan Murphy / Daragh O'Reilly

Tel: [phone]

About Ovoca Bio

Ovoca Bio is a European-based biopharmaceutical company with a focus on women's health. The Company is currently developing Orenetide (BP-101), a novel synthetic peptide administered through a nasal spray as a novel treatment for women with hypoactive sexual desire disorder (HSDD), a condition characterized by a distressing lack or loss of sexual desire affecting an estimated 4 million premenopausal women in the US alone.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLFIFSRLRIVFIS

(END) Dow Jones Newswires

January 23, 2024 02:00 ET (07:00 GMT)